Aztreonam-Avibactam: Mechanisms, Activity, and Clinical Use

Aztreonam-avibactam is an antibiotic combination designed to treat infections caused by some of the most drug-resistant bacteria known to medicine. It pairs aztreonam, a decades-old antibiotic that naturally resists destruction by one dangerous class of bacterial enzymes, with avibactam, a newer compound that blocks the other enzyme classes bacteria use to fight off antibiotics. The result is a drug that can overcome resistance mechanisms that individually defeat nearly every other available treatment, including last-resort carbapenems. Approved by the FDA in 2025, the fixed-dose combination fills a gap that infectious disease specialists have been trying to bridge with improvised drug cocktails for years.

The Problem It Was Built to Solve

Bacteria that produce metallo-β-lactamases (MBLs) represent one of the most pressing threats in infectious disease. These enzymes chew through nearly all β-lactam antibiotics, including carbapenems, the drugs typically reserved for the worst multidrug-resistant infections. The global spread of MBL-producing bacteria, particularly among gut-dwelling species in the Enterobacterales order, has outpaced the development of new antibiotics capable of treating them.¹ Before aztreonam-avibactam reached the market, clinicians often had to rely on toxic older drugs like colistin or cobble together multi-drug regimens without strong evidence to guide them.²

The challenge is compounded by the fact that MBL-producing bacteria rarely carry just one resistance mechanism. They frequently co-produce other classes of β-lactamases as well, which means a drug that dodges the MBL may still be destroyed by a different enzyme in the same organism. This layering of defenses is what makes these infections so difficult and is precisely the problem the aztreonam-avibactam combination was engineered to address.

How the Two Drugs Work Together

Aztreonam belongs to a class of antibiotics called monobactams. Its molecular structure gives it a natural advantage: MBLs, which are zinc-dependent enzymes, cannot break it down. That sounds like it should solve the problem on its own, but it does not. Most MBL-producing bacteria also produce serine β-lactamases, enzymes from different structural families that destroy aztreonam readily. Used alone, aztreonam fails against these organisms because their other enzymes still degrade it.³

Avibactam is a β-lactamase inhibitor that blocks serine β-lactamases, including extended-spectrum β-lactamases (ESBLs), AmpC enzymes, and carbapenemases like KPC and OXA-48. It does not, however, inhibit MBLs. On its own, avibactam would leave the MBL untouched. The elegance of the pairing is that neither drug needs to handle the MBL. Aztreonam is inherently stable against MBLs, and avibactam neutralizes the co-produced serine enzymes that would otherwise destroy aztreonam. Together, they cover all four major structural classes of β-lactamases.⁴

Lab Activity Against Drug-Resistant Bacteria

Global surveillance data paint a striking picture of how broadly aztreonam-avibactam works in the laboratory. In samples collected worldwide, the combination inhibited over 99% of all Enterobacterales tested, including extensively drug-resistant and carbapenem-resistant isolates. Against bacteria producing specific carbapenemases, activity remained exceptionally high: it inhibited 100% of KPC-producing isolates and about 99% of MBL-carrying isolates at a clinically relevant concentration.⁵ A separate global dataset from 2019 confirmed these findings, showing consistent activity across geographic regions, with over 99% susceptibility rates maintained against multidrug-resistant and MBL-positive isolates.⁶

The combination also shows activity against certain non-fermenting organisms. Stenotrophomonas maltophilia, a difficult-to-treat bacterium intrinsically resistant to carbapenems, produces two β-lactamases called L1 (a metallo-enzyme) and L2 (a serine enzyme). The same logic applies: aztreonam is stable against L1, and avibactam inhibits L2, so the combination can overcome aztreonam resistance in selected strains.⁷ The picture is more nuanced in practice, though. When both L1 and L2 are highly expressed alongside efflux pumps, activity can diminish.⁸ Against Pseudomonas aeruginosa, another important pathogen, surveillance data show consistent but somewhat less uniform activity than against Enterobacterales, particularly when MBL production is combined with other resistance mechanisms like porin loss or efflux pump overexpression.⁹

What the Clinical Trials Showed

The pivotal REVISIT trial compared aztreonam-avibactam to meropenem, a standard carbapenem, in patients with complicated abdominal infections or hospital-acquired and ventilator-associated pneumonia. In the overall population, about 68% of patients receiving aztreonam-avibactam achieved clinical cure, compared with about 66% in the meropenem group. Among abdominal infection patients specifically, cure rates were roughly 76% for aztreonam-avibactam and 74% for meropenem. For the sicker pneumonia patients, cure rates were lower in both arms but again comparable: about 46% versus 42%. Mortality at 28 days was 4% in the aztreonam-avibactam group and 7% in the meropenem group. The combination was well tolerated with no treatment-related serious adverse events reported.¹⁰

The REVISIT trial was designed to demonstrate non-inferiority to meropenem, meaning it showed aztreonam-avibactam is at least as effective as a standard-of-care carbapenem. That matters because the real value of the drug is against organisms that carbapenems cannot touch. For those infections, REVISIT provides baseline safety and efficacy data while a separate trial addressed the harder question.

That separate trial, ASSEMBLE, specifically enrolled patients with confirmed MBL-producing infections, the population aztreonam-avibactam was most urgently needed for. Enrollment was extremely limited because these patients are difficult to identify and recruit, and many are already on other antibiotics by the time results come back. Only 15 patients were randomized. Among the 12 who received aztreonam-avibactam, five (42%) achieved clinical cure at the test-of-cure visit, compared with zero of three patients who received the best available alternative therapy. Mortality at 28 days was 8% in the aztreonam-avibactam arm versus 33% in the comparator arm. These numbers are too small to draw definitive statistical conclusions, but the directional signal, combined with the REVISIT data and in vitro evidence, supported regulatory approval.¹¹

Real-World Data on MBL Bloodstream Infections

Before the fixed-dose product existed, clinicians improvised by giving ceftazidime-avibactam (an already approved drug) alongside separate aztreonam infusions. A multicenter study emulating a target trial compared this improvised combination against other active antibiotics in patients with MBL-producing Enterobacterales bloodstream infections. The ceftazidime-avibactam plus aztreonam group had a 30-day mortality rate of about 35%, compared with roughly 47% among patients receiving other active antibiotics. After statistical adjustment, this translated to about a 37% lower odds of death. Clinical failure was also less common: 46% versus 53%, and it occurred later in the combination group. Adverse events were less frequent as well, at about 10% versus 23%.¹²

These real-world results provide important context. The patients were severely ill, mortality was high in both groups, and the study was observational. But the consistent direction of benefit across mortality, clinical failure, and adverse events bolsters confidence that the aztreonam-plus-avibactam approach has genuine clinical value in MBL infections.

Why a Fixed Combination Beats the Improvised Version

Before 2025, if you wanted to give a patient aztreonam and avibactam together, you had to administer ceftazidime-avibactam (the only available avibactam-containing product) as one infusion and aztreonam as a separate infusion. This workaround was logistically complex and pharmacologically imperfect. Ceftazidime-avibactam and aztreonam are dosed on different schedules and have different infusion times, which means the peak concentrations of avibactam and aztreonam may not align. If avibactam levels dip before aztreonam has finished its work, the serine β-lactamases can briefly resume destroying aztreonam, reducing effectiveness.

The fixed-dose combination eliminates this timing problem. Both drugs are in the same bag, infused simultaneously, ensuring predictable co-exposure throughout the dosing interval. Pharmacokinetic modeling has shown that the approved aztreonam-avibactam regimen achieves its joint drug-exposure targets in roughly 89% to over 99% of patients at steady state, depending on kidney function. By contrast, the ceftazidime-avibactam plus aztreonam regimens proposed by guidelines achieved joint target attainment below 85%, primarily because avibactam exposures were insufficient.¹³ A comparative review noted that observational data tend to look more favorable for aztreonam-avibactam than for the improvised combination, though head-to-head comparisons have not been conducted.¹⁴

Dosing and Kidney Function Adjustments

The approved regimen for adults with normal kidney function involves a short loading dose followed by maintenance infusions every six hours, each given over three hours. Avibactam’s concentration is the main driver of whether the drug-exposure targets are met, so the dosing was engineered around keeping avibactam levels high enough between doses.¹⁵ The loading dose helps both drugs reach effective levels quickly rather than waiting for concentrations to build up over several cycles.

Because both aztreonam and avibactam are cleared through the kidneys, dose adjustments are needed when kidney function is reduced. For patients with moderate impairment, both doses and intervals are adjusted. For severe impairment, a simplified half-dose regimen given every eight hours over two-hour infusions appears to achieve exposure targets comparable to the full labeled regimen, offering a practical option for these patients.¹⁶ One consistent finding across modeling studies is that the three-hour infusion duration is important for patients with normal or near-normal kidney function; shortening it to one or two hours can reduce target attainment. For patients with lower kidney function, the drug clears more slowly, so shorter infusion times may still work.

How Resistance Can Emerge

No antibiotic is immune to resistance, and aztreonam-avibactam is no exception. The mechanisms that reduce its effectiveness are different from those that affect carbapenems, but they exist. The most studied involves changes to penicillin-binding protein 3 (PBP3), the molecular target that aztreonam must reach inside the bacterial cell to kill it. Some strains, particularly certain Escherichia coli, carry a four-amino-acid insertion in PBP3 that physically blocks aztreonam from accessing its binding site. An isogenic mutant study confirmed this insertion raises the concentration of aztreonam needed to inhibit the bacteria.¹⁷

This is not a rare curiosity. Surveillance in India found a high prevalence of E. coli clinical isolates carrying these PBP3 insertions, suggesting that in regions with heavy MBL burden, aztreonam-avibactam may face reduced susceptibility even at launch.¹⁸ Beyond PBP3 changes, bacteria can reduce susceptibility through porin mutations that limit how much drug gets into the cell and efflux pump overexpression that pumps it back out. In some isolates, elevated aztreonam-avibactam concentrations needed for inhibition could be reversed by adding an efflux pump inhibitor, confirming the role of efflux.

Comparing resistance profiles with cefiderocol, the other recently approved agent active against MBL producers, reveals a somewhat complementary picture. Cefiderocol’s effectiveness is primarily undermined by NDM production, reduced expression of iron transporters the drug exploits to enter the cell, and PBP3 alterations. Regional susceptibility differences are notable: cefiderocol susceptibility among MBL-producing Enterobacterales varies between Asia and North America or Europe. Aztreonam-avibactam’s resistance drivers are more focused on PBP3 insertions, porins, and efflux. For clinicians, the practical implication is that the two drugs are not interchangeable: a strain resistant to one may still be susceptible to the other.¹⁹

Testing Challenges in Clinical Laboratories

Knowing that aztreonam-avibactam works in theory only helps if the lab can reliably tell clinicians whether a specific patient’s infection will respond to it. Susceptibility testing for combination drugs is more complex than for a single antibiotic, because the lab must deliver the correct ratio of both agents to the bacterial sample. Several methods have been evaluated, including disk diffusion, gradient test strips, and broth-based methods. In a comparison using broth disk elution as the reference standard, disk diffusion and gradient strip methods both achieved 100% categorical agreement, meaning they correctly classified strains as susceptible or resistant every time.²⁰

A separate evaluation found that a commercially available gradient test strip achieved about 97% agreement with the reference method for carbapenemase-producing Enterobacterales and about 89% for S. maltophilia. The strip was selected as the preferred method for routine clinical laboratory testing based on its balance of accuracy, reproducibility, and ease of use.²¹ Getting testing right matters especially because of those PBP3 insertion-carrying strains: without accurate susceptibility data, a clinician might assume aztreonam-avibactam will work when it will not.

Safety Profile

Across trials, aztreonam-avibactam has been generally well tolerated. In the REVISIT trial, there were no treatment-related serious adverse events in the aztreonam-avibactam arm, and the safety profile was consistent with what has long been known about aztreonam given alone.²² The most commonly reported side effects involve the liver: transient elevations in liver enzymes have been the most frequent adverse finding across studies.²³

One safety feature worth noting is that aztreonam has an unusually low cross-reactivity profile with penicillin allergy. Unlike most β-lactams, its monobactam structure means it can often be used safely in patients with penicillin or cephalosporin allergies, though careful evaluation is still warranted in individual cases. This gives aztreonam-avibactam a practical advantage over carbapenems and cephalosporins in allergy-constrained patients dealing with resistant infections.

Cost-Effectiveness in a High-Resistance Setting

New antibiotics for resistant organisms are often expensive, and health systems need to weigh that cost against outcomes. A cost-effectiveness analysis modeled in Spain compared aztreonam-avibactam to colistin plus meropenem, a regimen commonly used as a fallback for MBL infections. The analysis found that aztreonam-avibactam added about €1,876 in cost per patient but gained roughly 0.6 quality-adjusted life years, translating to a cost per quality-adjusted life year gained of about €3,116. For abdominal infections specifically, this figure dropped to about €1,284 per quality-adjusted life year. In about 15% of simulated scenarios, aztreonam-avibactam was both less costly and more effective than the comparator, making it dominant.²⁴ By conventional health-economic thresholds, these numbers strongly favor the new combination over the older toxic regimen.

Gaps That Remain

Pediatric data for the fixed-dose combination are still limited. Dose selection for adults relied heavily on pharmacokinetic modeling and simulation rather than massive trial populations, and extending those models to children involves additional complexity around drug clearance rates that change with age and body size. Similarly, data in patients on hemodialysis or other forms of renal replacement therapy are thin, though modeling work for end-stage kidney disease has been part of the dose-optimization program.¹³

There is also no large randomized trial directly comparing the fixed-dose product to the improvised ceftazidime-avibactam plus aztreonam regimen. The pharmacokinetic modeling and observational data favor the fixed combination, but infectious disease practice often lags behind approvals, and many hospitals will continue using what they already have on formulary until the fixed product is widely stocked. Monitoring resistance trends, especially the spread of PBP3 insertions in high-burden regions, will be critical for understanding how durable the drug’s effectiveness will be over the coming years.